Latest News
There are two companies investors should consider for bargain values.
Via The Motley Fool · May 17, 2026
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Via The Motley Fool · May 17, 2026
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Via The Motley Fool · May 17, 2026
Horizon Quantum Computing Pte. (NASDAQ:HQ) used its appearance at Needham & Company’s 21st annual Technology, Media, & Consumer Conference to outline its strategy as a newly public quantum software company focused on building infrastructure for developers, hardware providers and end users.
Needham
Via MarketBeat · May 17, 2026
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
Via The Motley Fool · May 17, 2026
Nvidia dominates artificial intelligence (AI) on Earth – and it should do the same for AI in space.
Via The Motley Fool · May 17, 2026
Full Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services.
Via The Motley Fool · May 17, 2026
GDS Holdings develops and operates data centers in China, serving major cloud, internet, and financial sector clients.
Via The Motley Fool · May 17, 2026
Alphabet has a huge advantage with its TPUs, which it developed more than a decade ago.
Via The Motley Fool · May 17, 2026
Plug Power served up some promising news for investors this week.
Via The Motley Fool · May 17, 2026
There's no cut-and-dried answer about the best time to sign up for benefits.
Via The Motley Fool · May 17, 2026
Snap is unprofitable after almost 15 years and doesn't have the revenue growth rates of an exciting start-up.
Via The Motley Fool · May 17, 2026
Methanex supplies methanol worldwide, using integrated operations and its own fleet to serve industrial clients across major global markets.
Via The Motley Fool · May 17, 2026
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
Via The Motley Fool · May 17, 2026
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
Via The Motley Fool · May 17, 2026
Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
Via The Motley Fool · May 17, 2026
Palantir remains a high-variance AI infrastructure bet where narrative and execution will matter equally over the next decade.
Via The Motley Fool · May 17, 2026
Poet's new contract announcement powered huge gains for the stock.
Via The Motley Fool · May 17, 2026
This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.
Via The Motley Fool · May 17, 2026
Ares Capital isn't worried about last quarter's challenges.
Via The Motley Fool · May 17, 2026
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Via The Motley Fool · May 17, 2026
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Via The Motley Fool · May 17, 2026
Buying the S&P 500 instead of the Qs could help you avoid relying too heavily on tech stocks.
Via The Motley Fool · May 17, 2026
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Via The Motley Fool · May 17, 2026
These memory chipmakers have major expansion plans underway.
Via The Motley Fool · May 17, 2026
